5,858 results match your criteria Hypophosphatemia


Tumor-induced osteomalacia.

Osteoporos Sarcopenia 2018 Dec 12;4(4):119-127. Epub 2018 Dec 12.

Department of Endocrinology, Key Laboratory of Endocrinology, The National Commission of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Tumor-induced osteomalacia (TIO), also known as oncogenic osteomalacia, is a rare paraneoplastic syndrome characterized by hypophosphatemia resulting from decreased tubular phosphate reabsorption, with a low or inappropriately normal level of active vitamin D. The culprit tumors of TIO could produce fibroblast growth factor 23 which plays a role in regulating renal Pi handling and 25-hydroxyvitamin D 1α-hydroxylase activity. Chronic hypophosphatemia could eventually lead to inadequate bone mineralization, presenting as osteomalacia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.afos.2018.12.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372818PMC
December 2018

Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: Utility of the radiographic Rickets Severity Score.

Bone 2019 Feb 14. Epub 2019 Feb 14.

Yale University School of Medicine, New Haven, CT, USA.

The Rickets Severity Score (RSS) was used to evaluate X-linked hypophosphatemic rickets (XLH), a genetic disorder mediated by increased circulating FGF23. The reliability of the RSS was assessed using data from a randomized, phase 2 clinical trial that evaluated the effects of burosumab, a fully human anti-FGF23 monoclonal antibody, in 52 children with XLH ages 5 to 12 years. Bilateral knee and wrist radiographs were obtained at baseline, week 40, and week 64. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bone.2019.02.010DOI Listing
February 2019

Hypocalcemia and hypophosphatemia after treatment with zoledronic acid in a patient with AL amyloidosis.

Intern Emerg Med 2019 Feb 15. Epub 2019 Feb 15.

Regional Reference Centre for Coagulation Disorders, Department of Clinical Medicine and Surgery, "Federico II" University of Naples, Via S. Pansini, 5, 80131, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11739-019-02048-wDOI Listing
February 2019

Hypercalcaemic Crisis Due to Primary Hyperparathyroidism: Report of Two Cases.

J Crit Care Med (Targu Mures) 2019 Jan 4;5(1):34-39. Epub 2019 Feb 4.

University of Medicine, Pharmacy, Sciences and Technology of Târgu Mureş, Romania.

Introduction: A hypercalcaemic crisis, also called para thyrotoxicosis, hyper parathyroid crisis or parathyroid storm, is a complication of primary hyperparathyroidism (PHPT) and an endocrinology emergency that can have dramatic or even fatal consequences if it is not recognised and treated in time.

Case Presentation: Two cases presented in the emergency department with critical hypercalcaemic symptoms and severe elevation of serum calcium and parathyroid hormone levels, consistent with a hypercalcaemic crisis. The first case, a 16-year-old female patient, had imaging data that highlighted a single right inferior parathyroid adenoma and a targeted surgical approach was used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2478/jccm-2019-0004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369571PMC
January 2019

Fluconazole as a New Therapeutic Tool to Manage Patients With NPTIIc (SLC34A3) Mutation: A Case Report.

Am J Kidney Dis 2019 Feb 11. Epub 2019 Feb 11.

Centre de Référence des Maladies Rénales Rares, filière ORKID, Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques; Centre de Référence des Maladies Rares du Calcium et du Phosphate, filière OSCAR; Faculté de Médecine Lyon Est, Université Lyon 1, Lyon; INSERM 1033, Prévention des Maladies Osseuses, Lyon, France. Electronic address:

Mutations in the SLC34A3 gene, encoding the sodium/phosphate cotransporter 2C (NPTIIc), induce decreased renal phosphate reabsorption, hypophosphatemia, decreased fibroblast growth factor 23 and parathyroid hormone, and increased 1,25-dihydroxyvitamin D (1,25[OH]D) levels. The complete phenotype is characterized by hypophosphatemia, hypercalciuria, and nephrolithiasis/nephrocalcinosis, leading to chronic kidney disease and osteoporosis in adults. We report a 15-year-old boy referred for nephrocalcinosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.ajkd.2018.12.026DOI Listing
February 2019

A Familial Case of a Whole Germline CDC73 Deletion Discordant for Primary Hyperparathyroidism.

Horm Res Paediatr 2019 Feb 8:1-8. Epub 2019 Feb 8.

Department of Pediatrics, National Hospital Organization Tokyo Medical Center, Tokyo,

Introduction: Primary hyperparathyroidism (PHPT) occurs as part of familial syndromes, including CDC73-related disorders caused by germline pathogenic variants of the CDC73 gene, particularly in early adulthood. Herein, we report a familial case of a whole germline CDC73 deletion discordant for PHPT.

Case Description: A 15-year-old boy was admitted to our hospital because of persistent nausea and vomiting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495800DOI Listing
February 2019
1 Read

Tumor-induced osteomalacia: experience from three tertiary care centres In India.

Endocr Connect 2019 Feb 1. Epub 2019 Feb 1.

V Agashe, Orthopaedics, PD Hinduja National Hospital and Medical Research Centre, Mumbai, India.

Tumour-induced osteomalacia (TIO) is a rare para-neoplastic syndrome characterized by recalcitrant hypophosphatemia. Reports from the Indian subcontinent are scarce, with most being single center experiences involving few patients. Herein, we conducted a retrospective analysis of 30 patients of TIO diagnosed at three tertiary care hospitals in India. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EC-18-0552DOI Listing
February 2019
1 Read

Vibrational spectroscopic analysis of hydroxyapatite in HYP mice and individuals with X-linked hypophosphatemia.

Ther Adv Chronic Dis 2018 11;9(12):268-281. Epub 2018 Oct 11.

Frank H. Netter MD School of Medicine, Quinnipiac University, 275 Mt. Carmel Avenue, NH-MED MNH-311H, Hamden, CT 06518, USA.

Background: X-linked hypophosphatemia (XLH) is the most common form of familial phosphate-wasting disorders, due to an inactivating mutation in the phosphate-regulating neutral endopeptidase, X-linked gene. Persistent osteomalacia, enthesophytes, osteophytes, degenerative arthritis and dental abscesses/periodontal disease dominate the adult disorder. However, the impact of insufficient phosphate on hydroxyapatite composition, the major inorganic component of bone and teeth, is unknown in individuals with XLH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040622318804753DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348532PMC
October 2018
1 Read

Editorial: Endocrine and Paracrine Role of FGF23 and Klotho in Health and Disease.

Authors:
Reinhold G Erben

Front Endocrinol (Lausanne) 2019 21;10. Epub 2019 Jan 21.

Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fendo.2019.00002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348246PMC
January 2019
1 Read

X-Linked Hypophosphatemia: Management and Treatment Prospects.

Joint Bone Spine 2019 Jan 31. Epub 2019 Jan 31.

Centre de référence des maladies rares du métabolisme du calcium et du phosphate, filière OSCAR and Plateforme d'Expertise Maladies Rares Paris-Sud, Hôpital Bicêtre Paris Sud, APHP, 94270 Le Kremlin Bicêtre, France; Endocrinologie et diabète de l'enfant, Hôpital Bicêtre Paris Sud, APHP, 94270 Le Kremlin Bicêtre, France; INSERM U1185 et université Paris Sud Paris-Saclay, Hôpital Bicêtre Paris Sud, 94270 Le Kremlin Bicêtre, France.

X-linked hypophosphatemia (XLH), due to a PHEX gene mutation, is the most common genetic form of rickets and osteomalacia. Manifestations in children consist of rickets, lower-limb bone deformities, bone pain, failure to thrive, dental abscesses, and/or craniostenosis. Adults may present with persistent bone pain, early osteoarthritis, hairline fractures and Looser zones, enthesopathy, and/or periodontitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbspin.2019.01.012DOI Listing
January 2019
1 Read

Elevated Bone Remodeling Markers of CTX and P1NP in Addition to Sclerostin in Patients with X-linked Hypophosphatemia: A Cross-Sectional Controlled Study.

Calcif Tissue Int 2019 Feb 1. Epub 2019 Feb 1.

Department of Pediatrics, Kolding Hospital at Lillebaelt Hospital, Kolding, Denmark.

Aspects of bone remodeling have only been scarcely studied in X-linked hypophosphatemia (XLH). In this cross-sectional controlled study, we assessed biochemical indices of bone remodeling and sclerostin in 27 adult patients (median age 47 [range 24-79] years, 19 women, 8 men) with XLH matched with 81 healthy control subjects (1:3) with respect to age-, sex-, and menopausal status. Markers of bone resorption (carboxyterminal cross-linked telopeptide of type 1 collagen, CTX) and formation (N-terminal propeptide of type 1 procollagen, P1NP) were higher in XLH patients compared to controls (median [IQR] 810 [500-1340] vs 485 [265-715] ng/l and 90 [57-136] vs 49 [39-65] ug/l, respectively, both p < 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00223-019-00526-zDOI Listing
February 2019
1 Read

Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study.

Lancet Haematol 2019 Jan 28. Epub 2019 Jan 28.

Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.

Background: Patients with acute myeloid leukaemia frequently have thrombocytopenia during induction chemotherapy. Eltrombopag, an oral thrombopoietin receptor agonist, stimulates platelet production by a similar mechanism to endogenous thrombopoietin. This study investigated safety and efficacy of eltrombopag versus placebo during anthracycline-based induction treatment of patients with acute myeloid leukaemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(18)30231-XDOI Listing
January 2019
1 Read

Hyperemesis gravidarum followed by refeeding syndrome causes electrolyte abnormalities induced rhabdomyolysis and diabetes insipidus.

Endocr J 2019 Jan 29. Epub 2019 Jan 29.

Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.

Although hyperemesis gravidarum (HG), an extreme form of morning sickness, is a common complication during pregnancy, HG associated simultaneous onset of rhabdomyolysis and diabetes insipidus due to electrolyte abnormalities are rare. A 34-year-old woman with severe HG at 17 weeks of gestation complicated with appetite loss, weight reduction by 17 kg, general fatigue, myalgia, weakness and polyuria was identified to have simultaneous hypophosphatemia (1.6 mg/dL) and hypokalemia (2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1507/endocrj.EJ18-0496DOI Listing
January 2019
1 Read

Effects of diabetic ketoacidosis in the respiratory system.

World J Diabetes 2019 Jan;10(1):16-22

Division of Pulmonary, Critical Care and Sleep Medicine, Texas A and M University, Corpus Christy, TX 78412, United States.

Diabetes affects approximately 30 million persons in the United States. Diabetes ketoacidosis is one of the most serious and acute complications of diabetes. At the time of presentation and during treatment of diabetic ketoacidosis (DKA), several metabolic and electrolyte derangements can ultimately result in respiratory compromise. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4239/wjd.v10.i1.16DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347653PMC
January 2019
2 Reads

Clinical and genetic analysis in a large Chinese cohort of patients with X-linked hypophosphatemia.

Bone 2019 Jan 23;121:212-220. Epub 2019 Jan 23.

Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Shuaifuyuan No. 1, Wangfujing, Dongcheng District, Beijing 100730, China. Electronic address:

X-linked Hypophosphatemia (XLH) is caused by loss of function mutations in the PHEX gene. Given the recent availability of a new therapy for XLH, a retrospective analysis of the most recent 261 Chinese patients with XLH evaluated at Peking Union Medical College Hospital was conducted. Clinical, biochemical, radiographic studies, as well as genetic analyses, including Sanger sequencing for point mutations and Multiplex Ligation-dependent Probe Amplification (MLPA) to detect large deletions/duplications were employed. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S87563282193003
Publisher Site
http://dx.doi.org/10.1016/j.bone.2019.01.021DOI Listing
January 2019
4 Reads

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.

Br J Cancer 2019 Jan 25. Epub 2019 Jan 25.

UCL Cancer Institute, London, UK.

Background: This phase 1 study examined the safety, tolerability, pharmacokinetics and preliminary efficacy of eribulin-liposomal formulation (eribulin-LF) in patients with advanced solid tumours.

Methods: Eligible patients with ECOG PS 0-1 were treated with eribulin-LF either on day 1 every 21 days (Schedule 1), or on days 1 and 15 every 28 days (Schedule 2). Doses ranged from 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0377-xDOI Listing
January 2019
1 Read
4.836 Impact Factor

99mTc-HYNIC-TOC in the Evaluation of Recurrent Tumor-Induced Osteomalacia.

Clin Nucl Med 2019 Mar;44(3):209-213

Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing, China.

Purpose: Tumor-induced osteomalacia (TIO) is rare paraneoplastic disorder generally caused by small benign neoplasm. Somatostatin receptor imaging has emerged as imaging of the choice in the localization of the causative tumors in new patients with clinical diagnosis of TIO. An accurate localization of the causative tumor using somatostatin receptor imaging followed by successful surgical removal offers cure of the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002458DOI Listing
March 2019
1 Read

Chomping at the Bit: A Descriptive Report on Pediatric Clenbuterol Ingestion.

J Pharm Pract 2019 Jan 22:897190018823114. Epub 2019 Jan 22.

2 Department of Emergency Medicine, University of Kentucky-Chandler Medical Center, Lexington, KY, USA.

Introduction:: Clenbuterol hydrochloride is a selective beta-2 adrenergic agonist with uses in both humans and animals. Ingestions occurring within the United States are generally due to incidental ingestion of a veterinary product, use as a cutting agent for illicit substances, or illegal use for performance-enhancing purposes.

Case Report:: A four-and-a-half year-old male presented approximately two-and-a-half hours after an accidental ingestion of an unknown quantity of clenbuterol. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0897190018823114DOI Listing
January 2019
1 Read

Hypophosphatemia is Prevalent among Preterm Infants Less than 1,500 Grams.

Am J Perinatol 2019 Jan 21. Epub 2019 Jan 21.

Community Health Sciences, Institute of Public Health, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Objective:  This article identifies the prevalence and associated factors of hypophosphatemia (HP) in very low birth weight (VLBW) infants in the first week of life.

Study Design:  Prospective exploratory cohort study of 106 consecutive VLBW infants admitted to neonatal intensive care at Foothills Hospital, Calgary, Canada. HP was defined as at least one measurement of serum phosphate < 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0039-1677713DOI Listing
January 2019
2 Reads

Physiology of FGF23 and overview of genetic diseases associated with renal phosphate wasting.

Metabolism 2019 Jan 19. Epub 2019 Jan 19.

Paris Descartes University of Medicine, Necker-Enfants Malades Institute, INSERM U1151, France; Functional Exploration Department, Necker-Enfants Malades Hospital, AP-HP, Paris, France.

Phosphate is a cornerstone of several physiological pathways including skeletal development, bone mineralization, membrane composition, nucleotide structure, maintenance of plasma pH, and cellular signaling. The kidneys have a key role in phosphate homeostasis with three hormones having important functions in renal phosphate handling or intestinal absorption: parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and 1-25-dihydroxyvitamin D (1,25(OH)2D). FGF23 is mainly synthesized by osteocytes; it is a direct phosphaturic factor that also inhibits 1,25(OH)2D and PTH. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00260495193002
Publisher Site
http://dx.doi.org/10.1016/j.metabol.2019.01.006DOI Listing
January 2019
11 Reads

Joint replacement in X-linked hypophosphatemia.

J Orthop 2019 Jan-Feb;16(1):55-60. Epub 2018 Dec 21.

Department of Medical Sciences, Frank H. Netter MD School of Medicine at Quinnipiac University, Hamden, CT, 06518, USA.

X-linked hypophosphatemia (XLH) is associated with a pervasive, severe degenerative osteoarthritis. We conducted a retrospective chart review/patient survey using the Knee or Hip Osteoarthritis Outcome Score Physical Function Short Form. Fourteen total knee arthroplasties and 7 total hip arthroplasties among 11 patients were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jor.2018.12.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324762PMC
December 2018
2 Reads

Spinal phosphaturic mesenchymal tumors: Case report and literature review.

J Clin Neurosci 2019 Jan 16. Epub 2019 Jan 16.

Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shuaifuyuan 1, Dong Cheng District, Beijing 100730, China. Electronic address:

Tumor-induced osteomalacia (TIO) is regarded as a rare paraneoplastic syndrome generally caused by phosphaturic mesenchymal tumors (PMTs). As far as we know, only 18 spinal PMTs have been described in the world's English literature. The purpose of this study is to increase familiarity with its clinical features, diagnosis, and treatment of spinal PMTs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jocn.2019.01.010DOI Listing
January 2019
1 Read

Clinical utility of postoperative phosphate recovery profiles to predict liver insufficiency after living donor hepatectomy.

Am J Surg 2019 Jan 11. Epub 2019 Jan 11.

Division of Transplantation, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.

Background: Living donor hepatectomy (LDH) is associated with significant postoperative hypophosphatemia.

Methods: From January 1997 through July 2017, we performed 176 LDH and compared donors who developed liver insufficiency (LI) to those that did not within 30 days of LDH. Using smoothing splines, we constructed a mixed-effects model and assessed receiver operating characteristic curves. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjsurg.2019.01.006DOI Listing
January 2019
2 Reads

Hope for patients with X-linked hypophosphataemia?

Authors:
John M Pettifor

Lancet Diabetes Endocrinol 2019 Jan 9. Epub 2019 Jan 9.

SAMRC/Wits Developmental Pathways for Health Research Unit, Department of Paediatrics, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2050, South Africa. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-8587(19)30004-XDOI Listing
January 2019
1 Read

Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial.

Lancet Diabetes Endocrinol 2019 Jan 9. Epub 2019 Jan 9.

Indiana University School of Medicine, Indianapolis, IN, USA.

Background: Children with X-linked hypophosphataemia have high concentrations of circulating phosphatonin fibroblast growth factor 23 (FGF23), which causes renal phosphate wasting and hypophosphataemia, rickets, skeletal deformities, and growth impairment. Burosumab, a human monoclonal antibody against FGF23, improves phosphate homoeostasis and rickets in children aged 5-12 years with X-linked hypophosphataemia. We aimed to assess the safety and efficacy of burosumab in younger children with X-linked hypophosphataemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-8587(18)30338-3DOI Listing
January 2019
1 Read

Ectopic expression of Klotho in fibroblast growth factor 23 (FGF23)-producing tumors that cause tumor-induced rickets/osteomalacia (TIO).

Bone Rep 2019 Jun 31;10:100192. Epub 2018 Dec 31.

Fujii Memorial Institute of Medical Sciences, Tokushima University, Tokushima 770-8503, Japan.

Tumor-induced rickets/osteomalacia (TIO) is a rare paraneoplastic syndrome caused by tumors that ectopically express fibroblast growth factor 23 (FGF23). FGF23 is a bone-derived hormone that regulates serum phosphate concentrations. Patients with TIO develop hypophosphatemic rickets/osteomalacia due to FGF23 excess and suffer from symptoms such as leg deformities, bone pain, skeletal muscle myopathy, and multiple fractures/pseudofractures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bonr.2018.100192DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321977PMC
June 2019
3 Reads

Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review.

Bone 2019 Jan 4;121:60-67. Epub 2019 Jan 4.

Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45267, United States; Division of Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, United States.

Introduction: Intravenous bisphosphonates (IV BP) have been used to treat children with osteoporosis for many years. Favorable side effect profile and improvements in bone mineral density (BMD) have been demonstrated in patients with osteogenesis imperfecta (OI), a primary form of osteoporosis in pediatrics. Less is known about the safety of IV BP in children with secondary osteoporosis or glucocorticoid-induced osteoporosis (GIO). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bone.2019.01.003DOI Listing
January 2019
2 Reads

The clinical and pathological features of adefovir dipivoxil-related renal impairment
.

Clin Nephrol 2019 Jan 7. Epub 2019 Jan 7.

Aims: To investigate the clinicopathological features and outcomes of adefovir dipivoxil (ADV)-related renal impairment in Chinese patients.

Materials And Methods: Clinical, pathological, and follow-up data from 15 patients with ADV-related renal impairment were studied. Proximal renal tubular dysfunction (PRTD) was defined by the presence of at least two of the following four abnormalities: hypophosphatemia, hypouricemia, nondiabetic glucosuria, and proteinuria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5414/CN109574DOI Listing
January 2019
3 Reads
1.232 Impact Factor

Risk of cardiovascular involvement in pediatric patients with X-linked hypophosphatemia.

Pediatr Nephrol 2019 Jan 4. Epub 2019 Jan 4.

University of Oviedo, Oviedo, Spain.

Objective: To find out if cardiovascular alterations are present in pediatric patients with X-linked hypophosphatemia (XLH).

Study Design: Multicentre prospective clinical study on pediatric patients included in the RenalTube database ( www.renaltube. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00467-018-4180-3DOI Listing
January 2019
2 Reads

Effect of dietary phosphorus deprivation on leukocyte function in transition cows.

J Dairy Sci 2019 Feb 26;102(2):1559-1570. Epub 2018 Dec 26.

Department of Farm Animal Health, Faculty of Veterinary Medicine, 3584Cl Utrecht, the Netherlands; Clinic for Cattle, University of Veterinary Medicine Hannover, Foundation, 30173 Hanover, Germany. Electronic address:

Phosphorus depletion and hypophosphatemia have been described to hamper immune function in different species, an effect barely studied in dairy cows commonly developing hypophosphatemia in early lactation. Dietary P deprivation in mid lactating dairy cows was associated with a decline of the number of granulocytes and impaired granulocyte survival, whereas the phagocytic activity remained unaffected. The objective of the study reported here was to determine the effect of P deprivation on the leukocyte function of periparturient dairy cows. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00220302183113
Publisher Site
http://dx.doi.org/10.3168/jds.2018-15417DOI Listing
February 2019
12 Reads

Sinonasal hemangiopericytoma caused hypophosphatemic osteomalacia: A case report.

Medicine (Baltimore) 2018 Dec;97(52):e13849

Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu.

Rationale: Tumor-induced osteomalacia (TIO) is a rare, paraneoplastic syndrome featured with fibroblast growth factor 23 (FGF23) secretion primarily by benign mesenchymal tumors and sometimes by malignancies. TIO diagnosis and treatment is often delayed because TIO usually has nonspecific generalized bone pain and weakness, and location of TIO tumor is quite challenging. Very few TIO caused by sinonasal hemangiopericytoma have been reported in the literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013849DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314754PMC
December 2018
1 Read
5.723 Impact Factor

Vitamin D deficiency in immigrants.

Bone Rep 2018 Dec 11;9:37-41. Epub 2018 Jun 11.

Department of Internal Medicine, Endocrine Section, VU University Medical Center, Amsterdam, The Netherlands.

Vitamin D deficiency and rickets are more common in non-western immigrants and refugees than in the native population. Severe vitamin D deficiency (serum 25-hydroxyvitamin D <25 nmol/l) may occur in up to 50% of children and adults of non-western origin. They are not used to sunshine exposure due to the often excessive sunshine in the country of origin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bonr.2018.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303232PMC
December 2018
5 Reads

Rhabdomyolysis and Acute Poisoning; a Brief Report.

Emerg (Tehran) 2018 26;6(1):e56. Epub 2018 Sep 26.

Loghman-Hakim Hospital Poison Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Introduction: Some studies have reported creatinine phosphokinase (CPK) as a new emerging way in predicting the outcomes of poisoned patients. This study aimed to evaluate the association of serum CPK level in the first 24 hours with outcomes of poisoned patients.

Methods: This retrospective cross-sectional study was performed using the medical profiles of poisoned patients aged between 13 and 70 years old who were referred to the emergency department of a big referral medical toxicology center during 6 years and whose necessary data for this study was available. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289148PMC
September 2018
1 Read

Efficacy and safety of a phosphate replacement strategy for severe hypophosphatemia in the ICU.

Neth J Med 2018 Dec;76(10):437-441

Department of Internal Medicine, Rijnstate Hospital, Arnhem, the Netherlands.

Background: Experience with individualized phosphate replacement is limited in patients with severe hypophosphatemia. This study compares the efficacy and safety of an individualized regimen of serum phosphate < 0.4 mmol/l treatment in ICU patients to patients with moderate hypophosphatemia (0. Read More

View Article

Download full-text PDF

Source
December 2018
1 Read

Kidney Biopsy Findings in a Patient With Valproic Acid-Associated Fanconi Syndrome.

Pediatr Dev Pathol 2018 Dec 19:1093526618819334. Epub 2018 Dec 19.

2 Department of Pathology, Zucker School of Medicine, Hofstra University, Hempstead, New York.

A 7-year-old boy with a history of febrile illness-related epilepsy syndrome presented with proteinuria and elevated creatinine. His severe epileptic disorder has been treated since age 2 with multiple antiepileptic medications, including valproic acid. More recently, he was noted to have features of Fanconi syndrome with acidosis, hypophosphatemia, hypokalemia, glucosuria, and nephrotic-range proteinuria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1093526618819334DOI Listing
December 2018
1 Read

A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.

Cancer 2018 Dec 18. Epub 2018 Dec 18.

National Institute for Occupational Safety and Health (NIOSH) Research Branch, Centers for Disease Control and Prevention, Pittsburgh, Pennsylvania.

Background: Biliary tract cancers are rare, aggressive neoplasms. Most patients present with advanced/unresectable or metastatic disease at diagnosis, and no second-line regimen has demonstrated clinical benefit. This was a phase 2 study evaluating the efficacy and safety of regorafenib in patients who had advanced/unresectable or metastatic disease after receiving standard therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31872DOI Listing
December 2018
1 Read

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.

Lancet Haematol 2019 Jan 14;6(1):e38-e47. Epub 2018 Dec 14.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Background: Patients with relapsed or refractory high-risk chronic lymphocytic leukaemia or mantle cell lymphoma often do not derive durable benefit from ibrutinib monotherapy. We hypothesised that dual B-cell receptor pathway blockade would be tolerable and efficacious. We investigated a next-generation phosphoinositide-3-kinase-δ inhibitor (PI3K-δi), umbralisib, plus a Bruton tyrosine kinase inhibitor (BTKi), ibrutinib, in relapsed or refractory chronic lymphocytic leukaemia and mantle cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(18)30196-0DOI Listing
January 2019
1 Read

Hypophosphataemia in severe acute malnutrition: a prospective observational study.

Br J Nutr 2018 Dec 17:1-6. Epub 2018 Dec 17.

1Department of Paediatrics,King George's Medical University,Lucknow,Uttar Pradesh,226003,India.

Severe acute malnutrition (SAM) is a major cause of child mortality and morbidity. Children treated for SAM are at risk of refeeding hypophosphataemia (HP). The study was done to find out the incidence and various predictors of moderate/severe HP in SAM among North Indian children. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S0007114518003197DOI Listing
December 2018
1 Read

Clinical aspects of the phosphate transporters NaPi-IIa and NaPi-IIb: mutations and disease associations.

Pflugers Arch 2019 Jan 13;471(1):137-148. Epub 2018 Dec 13.

Institute of Physiology, University of Zurich, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland.

The Na-dependent phosphate transporter NaPi-IIa (SLC34A1) is mostly expressed in kidney, whereas NaPi-IIb (SLC34A2) has a wider tissue distribution with prominent expression in the lung and small intestine. NaPi-IIa is involved in renal reabsorption of inorganic phosphate (Pi) from urine, and patients with biallelic inactivating mutations in SLC34A1 develop hypophosphatemia, hypercalcemia, hypercalciuria and nephrocalcinosis, and nephrolithiasis in early childhood. Monoallelic mutations are frequent in the general population and may impact on the risk to develop kidney stones in adulthood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00424-018-2246-5DOI Listing
January 2019
1 Read

Successful Localization Using Ga-DOTATOC PET/CT of a Phosphaturic Mesenchymal Tumor Causing Osteomalacia in a Patient with Concurrent Follicular Lymphoma.

Nucl Med Mol Imaging 2018 Dec 12;52(6):462-467. Epub 2018 Sep 12.

1Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505 South Korea.

Diagnosing tumor-induced osteomalacia is often challenging because conventional imaging modalities may fail to locate the responsible tumor. This report describes the ability of Ga-DOTATOC PET/CT to successfully distinguish between the responsible phosphaturic mesenchymal tumor and concurrent lymphoma lesions. A 52-year-old man with bone pain for several years was diagnosed with a vitamin D-resistant hypophosphatemic osteomalacia. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13139-018-0546-5
Publisher Site
http://dx.doi.org/10.1007/s13139-018-0546-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261860PMC
December 2018
6 Reads

Randomized trial of intravenous iron-induced hypophosphatemia.

JCI Insight 2018 Dec 6;3(23). Epub 2018 Dec 6.

AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, USA.

Background: Hypophosphatemia can complicate intravenous iron therapy, but no head-to-head trials compared the effects of newer intravenous iron formulations on risks and mediators of hypophosphatemia.

Methods: In a randomized, double-blinded, controlled trial of adults with iron deficiency anemia from February 2016 to January 2017, we compared rates of hypophosphatemia in response to a single FDA-approved course of ferric carboxymaltose (n = 1,000) or ferumoxytol (n = 997). To investigate pathophysiological mediators of intravenous iron-induced hypophosphatemia, we nested within the parent trial a physiological substudy (ferric carboxymaltose, n = 98; ferumoxytol, n = 87) in which we measured fibroblast growth factor 23 (FGF23), calcitriol, and parathyroid hormone (PTH) at baseline and 1, 2, and 5 weeks later. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/jci.insight.124486DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328019PMC
December 2018
17 Reads

Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial.

Lancet Infect Dis 2018 Nov 24;18(11):1241-1250. Epub 2018 Oct 24.

Wits RHI, University of the Witwatersrand, Johannesburg, South Africa.

Background: Young women in southern Africa have substantial risk of HIV acquisition. Female-controlled biomedical interventions are needed to mitigate this risk. We aimed to assess the safety and efficacy of a pericoitally applied tenofovir 1% gel. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1473-3099(18)30428-6DOI Listing
November 2018
3 Reads

Lower phosphate levels following pancreatectomy is associated with postoperative pancreatic fistula formation.

HPB (Oxford) 2018 Nov 29. Epub 2018 Nov 29.

Harvard Medical School, 25 Shattuck St., Boston, MA 02115, USA; Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114, USA. Electronic address:

Background: Whereas hypophosphatemia following hepatectomy is associated with decreased morbidity, hypophosphatemia following pancreatectomy may be associated with increased morbidity, including the development of postoperative pancreatic fistula (POPF). This study aimed to evaluate the relationship between postoperative hypophosphatemia and POPF formation.

Methods: Patients from our institutional Research Patient Data Registry who underwent pancreatectomy from 2001 to 2017 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hpb.2018.10.017DOI Listing
November 2018
5 Reads

Prevalence of Metabolic Bone Disease in Tube-Fed Children Receiving Elemental Formula.

Horm Res Paediatr 2018 Nov 29:1-8. Epub 2018 Nov 29.

Division of Pediatric Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.

Background: Previous studies suggest normal mineral status in children receiving elemental formula. However, a recent multicenter survey described 51 children who developed hypophosphatemia and bone disease while receiving elemental formula. Our aim is to determine the prevalence of metabolic bone disease in children receiving extensively hydrolyzed or amino acid-based formula. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000494726DOI Listing
November 2018
1 Read

An Approach to Hypophosphataemia

Ir Med J 2018 May 10;111(5):761. Epub 2018 May 10.

Dept of Endocrinology, St. Vincent’s University Hospital, Elm Park, Dublin 4

View Article

Download full-text PDF

Source
May 2018
1 Read

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

Cancer Discov 2018 Nov 28. Epub 2018 Nov 28.

Samsung Medical Center, Seoul, Korea.

fusions are oncogenic drivers of various tumors, including non-small cell lung cancers (NSCLC). The safety and antitumor activity of the multikinase RET inhibitor RXDX-105 were explored in a phase I/Ib trial. A recommended phase II dose of 275 mg fed daily was identified. Read More

View Article

Download full-text PDF

Source
http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-18-0839DOI Listing
November 2018
11 Reads

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.

Lancet Oncol 2019 Jan 23;20(1):120-133. Epub 2018 Nov 23.

Medical Oncology Department, Centre Léon Bérard, Lyon, France.

Background: Regorafenib has proven activity in patients with pretreated gastrointestinal stromal tumours and colorectal and hepatocellular carcinoma. We designed REGOBONE to assess the efficacy and safety of regorafenib for patients with progressive metastatic osteosarcoma and other bone sarcomas. This trial comprised four parallel independent cohorts: osteosarcoma, Ewing sarcoma, chondrosarcoma, and chordoma. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045183074
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(18)30742-3DOI Listing
January 2019
16 Reads

Burosumab in X-linked hypophosphatemia: a profile of its use in the USA.

Drugs Ther Perspect 2018 8;34(11):497-506. Epub 2018 Oct 8.

Springer, Private Bag 65901, Mairangi Bay, 0754 Auckland, New Zealand.

Burosumab (Crysvita), a fully human IgG1 monoclonal antibody directed at fibroblast growth factor 23 (FGF23), is indicated for the treatment of X-linked hypophosphatemia (XLH), a condition associated with excessive FGF23 production. It directly addresses the excessive FGF23 activity in patients with XLH by binding to FGF23, and inhibiting its signaling. This leads to increased gastrointestinal phosphate absorption and renal phosphate reabsorption, thereby improving serum phosphate levels, and, ultimately, bone mineralization and the risk of bone disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40267-018-0560-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223702PMC
October 2018
12 Reads

A case of entecavir-associated bullous fixed drug eruption and a review of literature.

Turk J Gastroenterol 2018 Nov 19. Epub 2018 Nov 19.

Department of Pathology, Necmettin Erbakan University School of Medicine, Konya, Turkey.

Fixed drug eruption (FDE) is a type of drug reaction characterized by localized erythema, hyperpigmentation, and bullous at the same site(s), generally observed following every intake of a causative drug. Delayed-type cellular hypersensitivity (Type IVC) is considered to play a role in FDE etiology. Several antibiotics, barbiturates, oral contraceptives, nonsteroidal anti-inflammatory drugs, laxative-containing phenolphthalein, metronidazole, and quinine are known to be the primary drugs responsible for FDE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5152/tjg.2018.17887DOI Listing
November 2018
19 Reads

Hypophosphatemic Rickets.

Pediatr Clin North Am 2019 02;66(1):179-207

The Research Institute of the McGill University Health Centre, 1001 Boulevard Décarie, Room EM1.2232, Montreal, Quebec H4A3J1, Canada.

Hypophosphatemic rickets, mostly of the X-linked dominant form caused by pathogenic variants of the PHEX gene, poses therapeutic challenges with consequences for growth and bone development and portends a high risk of fractions and poor bone healing, dental problems and nephrolithiasis/nephrocalcinosis. Conventional treatment consists of PO4 supplements and calcitriol requiring monitoring for treatment-emergent adverse effects. FGF23 measurement, where available, has implications for the differential diagnosis of hypophosphatemia syndromes and, potentially, treatment monitoring. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pcl.2018.09.004DOI Listing
February 2019
1 Read
2.198 Impact Factor